Jeffrey contributes to patent prosecution and strategic portfolio development by assisting partners who serve clients in the biotechnology, pharmaceutical, chemical, and medical technology sectors. Drawing on more than a decade of scientific leadership and research experience, he supports the translation of complex innovations into strong, commercially aligned intellectual‑property strategies.
Before entering the legal field, Jeffrey earned his doctorate in biology from The Ohio State University and held faculty appointments at the University of Maryland, Baltimore and Case Western Reserve University, where he secured NIH funding for his research. At CWRU, he was affiliated with both the Cardiovascular Research Institute and the Center for RNA Science and Therapeutics. During his academic career, he authored thirty‑eight peer‑reviewed scientific articles. He also directed CWRU’s Mouse Metabolic Phenotyping Core, a state‑of‑the‑art facility supporting academic and industry collaborators in evaluating metabolic responses to therapeutic interventions, including small‑molecule treatments for obesity and insulin resistance. His depth of scientific experience is reflected in his service as a grant reviewer for organizations such as University College London and the American College of Surgeons, his work on the editorial board of a respected basic‑science journal, and his peer‑review contributions to more than eighteen journals in cardiometabolic disease, immunology, and microRNA biology.
This research foundation gives Jeffrey practical insight into how technologies evolve from laboratory discovery to commercial application. He leverages this technical depth to support Dinsmore partners in assessing novelty and patentability and in helping develop intellectual‑property strategies that align with long‑term business and commercialization goals.
